Bristol OTC migraine labeling study shows "superficial" comprehension -- FDA's Lechter.
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL-MYERS LABELING STUDY SHOWS "SUPERFICIAL" UNDERSTANDING of the proposed OTC migraine statements for Excedrin Extra Strength, FDA Division of Drug Marketing, Advertising & Communications Social Science Analyst Karen Lechter, PhD, commented at a July 15 FDA advisory committee meeting. "Potential users who are probable migraine sufferers seem to understand the migraine-specific elements of the label," but that understanding "was at a rather superficial level," Lechter said.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning